| DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR | None | ||
| 200MG;8.33MG;50MG;33.33MG |
Less Than $1000 mn
|
||
| None | None | ||
| None | None | ||
| None | None | ||
| VIEKIRA XR includes dasabuvir, a hepatitis C virus non-nucleoside NS5B palm polymerase inhibitor, ombitasvir, a hepatitis C virus NS5A inhibitor, paritaprevir, a hepatitis C virus NS3/4A protease inhibitor, and ritonavir, a CYP3A inhibitor and is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV): • genotype 1b infection without cirrhosis or with compensated cirrhosis • genotype 1a infection without cirrhosis or with compensated cirrhosis for use in combination with ribavirin. | |||
|
Yes
| |||
| VIEKIRA XR | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 | Patent 15 | Patent 16 | Patent 17 | Patent 18 | Patent 19 | Patent 20 | Patent 21 | Patent 22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| *** ********* | ||||||||||||||||||||||
| ****-********* ****** *** **** ******* | *********** ********* * ****** ******** ********** | ******* *** ******** *** | ******* *** ******** *** | ****-********* ****** *** **** ******* | *********** ********* * ****** ******** ********** | ******* *** ******** *** | ******* *** ******** *** | ***** ************ | ****-***** ********* | ****-***** ********* | ************ *** ******* *** ******** *** | ****-********* ****** *** **** ******* | ***** ********* ****** ***** | ***** ********* ****** ***** | ***** ********* ****** ***** | ************ ******* ****** | ******* ***** | ********* ** * ************** | ***** ********** *************** ************ | ***** ************** ****** **** | ***** ************** ****** **** |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|